Vaxart Inc
NASDAQ:VXRT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
R
|
Ratos AB
STO:RATO B
|
SE |
|
Zealand Pharma A/S
CSE:ZEAL
|
DK |
Vaxart Inc
Other Current Liabilities
Vaxart Inc
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Vaxart Inc
NASDAQ:VXRT
|
Other Current Liabilities
$66m
|
CAGR 3-Years
280%
|
CAGR 5-Years
219%
|
CAGR 10-Years
43%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Current Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Current Liabilities
$92m
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
-15%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Current Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Exact Sciences Corp
NASDAQ:EXAS
|
Other Current Liabilities
$9.5m
|
CAGR 3-Years
11%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
25%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Current Liabilities
$428.3m
|
CAGR 3-Years
11%
|
CAGR 5-Years
6%
|
CAGR 10-Years
30%
|
|
Vaxart Inc
Glance View
Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. The company is headquartered in South San Francisco, California and currently employs 110 full-time employees. Its programs include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV). The Company’s product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. The firm is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus.
See Also
What is Vaxart Inc's Other Current Liabilities?
Other Current Liabilities
66m
USD
Based on the financial report for Mar 31, 2025, Vaxart Inc's Other Current Liabilities amounts to 66m USD.
What is Vaxart Inc's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
43%
Over the last year, the Other Current Liabilities growth was 7 286%. The average annual Other Current Liabilities growth rates for Vaxart Inc have been 280% over the past three years , 219% over the past five years , and 43% over the past ten years .
